Terms: = Prostate cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
179 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
3. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
4. Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer.
Oshima M; Takayama KI; Yamada Y; Kimura N; Kume H; Fujimura T; Inoue S
Sci Rep; 2023 Nov; 13(1):19602. PubMed ID: 37950047
[TBL] [Abstract] [Full Text] [Related]
5. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
8. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer.
Kang N; Xue H; Lin YY; Dong X; Classen A; Wu R; Jin Y; Lin D; Volik S; Ong C; Gleave M; Collins C; Wang Y
Cancer Gene Ther; 2023 Oct; 30(10):1382-1389. PubMed ID: 37452083
[TBL] [Abstract] [Full Text] [Related]
9. Ligand-Directed H
Cai X; Zhang J; Ye H; Cui K; Hao T; Yi L; Yang X
Chemistry; 2023 Aug; 29(44):e202301105. PubMed ID: 37243903
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic Castration-Resistant prostate cancer, Immune Checkpoint Inhibitors, and Beyond.
Lanka SM; Zorko NA; Antonarakis ES; Barata PC
Curr Oncol; 2023 Apr; 30(4):4246-4256. PubMed ID: 37185436
[TBL] [Abstract] [Full Text] [Related]
11. Antibody-Drug Conjugates in prostate cancer: Where Are we?
Mjaess G; Aoun F; Rassy E; Diamand R; Albisinni S; Roumeguère T
Clin Genitourin Cancer; 2023 Feb; 21(1):171-174. PubMed ID: 35999150
[TBL] [Abstract] [Full Text] [Related]
12. Effects of GSK-J4 on JMJD3 Histone Demethylase in Mouse prostate cancer Xenografts.
Sanchez A; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
Cancer Genomics Proteomics; 2022; 19(3):339-349. PubMed ID: 35430567
[TBL] [Abstract] [Full Text] [Related]
13. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of prostate cancer.
Labanca E; Yang J; Shepherd PDA; Wan X; Starbuck MW; Guerra LD; Anselmino N; Bizzotto JA; Dong J; Chinnaiyan AM; Ravoori MK; Kundra V; Broom BM; Corn PG; Troncoso P; Gueron G; Logothethis CJ; Navone NM
Eur Urol Oncol; 2022 Apr; 5(2):164-175. PubMed ID: 34774481
[TBL] [Abstract] [Full Text] [Related]
14. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract] [Full Text] [Related]
15. Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.
Boibessot C; Joncas FH; Park A; Berrehail Z; Pelletier JF; Gris T; Bergeron A; Toren P
Sci Rep; 2021 Sep; 11(1):19299. PubMed ID: 34588590
[TBL] [Abstract] [Full Text] [Related]
16. Biologically informed deep neural network for prostate cancer discovery.
Elmarakeby HA; Hwang J; Arafeh R; Crowdis J; Gang S; Liu D; AlDubayan SH; Salari K; Kregel S; Richter C; Arnoff TE; Park J; Hahn WC; Van Allen EM
Nature; 2021 Oct; 598(7880):348-352. PubMed ID: 34552244
[TBL] [Abstract] [Full Text] [Related]
17. Phase I Study of Entinostat in Combination with Enzalutamide for treatment of Patients with Metastatic Castration-Resistant prostate cancer.
Lin J; Elkon J; Ricart B; Palmer E; Zevallos-Delgado C; Noonepalle S; Burgess B; Siegel R; Ma Y; Villagra A
Oncologist; 2021 Dec; 26(12):e2136-e2142. PubMed ID: 34427023
[TBL] [Abstract] [Full Text] [Related]
18. KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype.
Zhang B; Long Q; Wu S; Xu Q; Song S; Han L; Qian M; Ren X; Liu H; Jiang J; Guo J; Zhang X; Chang X; Fu Q; Lam EW; Campisi J; Kirkland JL; Sun Y
Nat Aging; 2021 May; 1(5):454-472. PubMed ID: 34263179
[TBL] [Abstract] [Full Text] [Related]
19. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor.
Jannu AK; Puppala ER; Gawali B; Syamprasad NP; Alexander A; Marepally S; Chella N; Gangasani JK; Naidu VGM
Int J Pharm; 2021 Aug; 605():120819. PubMed ID: 34166727
[TBL] [Abstract] [Full Text] [Related]
20. Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in cancer Signaling.
Ferguson HR; Smith MP; Francavilla C
Cells; 2021 May; 10(5):. PubMed ID: 34068954
[TBL] [Abstract] [Full Text] [Related]
[Next]
